<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022540</url>
  </required_header>
  <id_info>
    <org_study_id>PAN-01-101</org_study_id>
    <nct_id>NCT02022540</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD</brief_title>
  <official_title>A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PanOptica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PanOptica, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and tolerability of topical ocular
      PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with
      neovascular Age-Related Macular Degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Presence of any targeted adverse events (TAEs); safety endpoints include adverse events, vital signs, laboratory abnormalities, ophthalmic findings and outcomes</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Age-Related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>Stage 1 - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1- Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1- Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 - Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAN-90806 Ophthalmic Solution</intervention_name>
    <arm_group_label>Stage 1 - Group 1</arm_group_label>
    <arm_group_label>Stage 1 - Group 2</arm_group_label>
    <arm_group_label>Stage 1- Group 3</arm_group_label>
    <arm_group_label>Stage 1- Group 4</arm_group_label>
    <arm_group_label>Stage 1 - Group 5</arm_group_label>
    <arm_group_label>Stage 2</arm_group_label>
    <other_name>PAN-90806 Eye Drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <arm_group_label>Stage 2</arm_group_label>
    <other_name>ranibizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis in the study eye of active, pathologic, newly diagnosed and previously
             untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD

          -  Aged 50 years or older

          -  Demonstrate the ability, or have a family member who is willing and able, to instill
             topical ocular drops in the study eye

        Exclusion Criteria:

          -  No prior ocular or systemic treatment or surgery for neovascular AMD in the study eye

          -  History of or current clinical evidence in the study eye of:

               -  aphakia

               -  diabetic macular edema

               -  any ocular inflammation or infections

               -  pathological myopia

               -  retinal detachment

               -  advanced glaucoma

               -  significant media opacity, including cataract

          -  History or evidence of the following surgeries in the study eye:

               -  penetrating keratoplasty or vitrectomy;

               -  corneal transplant;

               -  corneal or intraocular surgery within 3 months of Screening

          -  Uncontrolled hypertension despite use of antihypertensive medications

          -  Participation in any investigational drug or device study, systemic or ocular, within
             past 3 months

          -  Women who are pregnant or nursing

          -  Known serious allergies or hypersensitivity to the fluorescein dye used in angiography
             or to the components of the PAN-90806 formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wax, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>PanOptica, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>wet AMD</keyword>
  <keyword>neovascular AMD</keyword>
  <keyword>exudative AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

